A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011 Dec; 63(12):3918-30.
-
Adult
-
Adult
-
Antibodies, Antinuclear
-
Antibodies, Antinuclear
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Monoclonal, Humanized
-
B-Cell Activating Factor
-
B-Cell Activating Factor
-
DNA
-
DNA
-
Dose-Response Relationship, Drug
-
Dose-Response Relationship, Drug
-
Double-Blind Method
-
Double-Blind Method
-
Female
-
Female
-
Humans
-
Humans
-
Lupus Erythematosus, Systemic
-
Lupus Erythematosus, Systemic
-
Male
-
Male
-
Middle Aged
-
Middle Aged
-
Severity of Illness Index
-
Severity of Illness Index
-
Treatment Outcome
-
Treatment Outcome